Developing novel therapeutics with a deep focus on modifying aging.
With a focus on prevention, we're developing a range of clinically validated therapeutic products that modify the way we age.
Robust investor returns facilitiated by a unique and integrated pipeline.
Currently developing ten leading programs with a clearly defined route to market.
With a focus on prevention, we're developing a range of clinically validated therapeutic products that modify the way we age.
Robust investor returns facilitated by a unique and integrated pipeline.
Currently developing ten leading programs with a clearly defined route to market.
Using an integrated hybrid model, we cover the entire aging market with a variety of advanced therapeutic technologies that target the biology of aging to treat multiple large indications.
Biotech company Morphoceuticals has announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor Juvenescence. Seed funding will advance programs using electroceuticals in limb regeneration and...
Juvenescence sponsored this article in Health, which discusses how your body can benefit from an efficient metabolism.
Dr. Greg Bailey, MD, CEO of Juvenescence, conducts an interview with M2Bio Sciences. In the interview, Greg shares his insights on Juvenescence, longevity biotech, entrepreneurship, and his personal story.
